Why Life Sciences M&A Should Heat up This Year

Episode Summary

Executive Summary: The episode examines EY’s view that 2018 would bring a surge in life sciences M&A, driven by abundant capital, tax reform, industry fragmentation, pricing pressure, divestitures, and rising competition from biotech, pharma, Asian buyers, and nontraditional players. Jeff Green argues that the sector’s deal environment is increasingly crowded and that the most attractive assets will require creative structures and rigorous valuation.

Main Topics: 2018 M&A outlook in life sciences (Priority: 5/5): EY expects a stronger year for dealmaking as tax uncertainty eases and capital remains abundant across the sector. Industry fragmentation and mega-merger potential (Priority: 5/5): The market remains highly fragmented, with no company exceeding 5% share, leaving room for consolidation and possible blockbuster deals. Tax reform, repatriation, and capital availability (Priority: 4/5): The U.S. tax bill and repatriation of offshore cash were seen as major catalysts that could unlock corporate spending on acquisitions. Divestitures and balance-sheet pressure (Priority: 4/5): Consumer health, specialty pharma, and generics companies may sell assets or become targets as leverage and growth pressure force portfolio reshaping. Competition among pharma, biotech, and nontraditional buyers (Priority: 5/5): Big Pharma and Big Bio are competing for assets, while Asian buyers and technology firms bring additional firepower and strategic interest. Creative deal structures and valuation discipline (Priority: 4/5): With desirable targets having alternatives, buyers will need strategic clarity, careful valuation, and structures that share risk and reward.

Key Arguments: The life sciences sector has ample financial capacity for acquisitions because cash, debt capacity, and market capitalization are collectively strong. Tax reform reduced uncertainty around repatriating offshore cash, improving the odds of more M&A in 2018. The industry remains fragmented, so consolidation is economically logical and could produce more mega-mergers. Pricing pressure, margin compression, and supply-chain rationalization remain major strategic reasons for large transactions. Divestitures are likely in consumer health and in over-levered specialty pharma/generics businesses that lack growth. Biotech companies face revenue replacement pressure from products losing patent protection or slowing growth, increasing their need to do deals. Asian investors, especially Chinese buyers, have the capital and strategic motives to invest in life sciences, including minority stakes that can delay exit events for smaller biotechs. Technology companies may move into healthcare infrastructure, the patient interface, and supply-chain efficiency rather than direct drug development. Because the best assets have multiple bidders and alternative funding sources, acquirers must be disciplined on valuation and creative in transaction design.

Data Points: Market share concentration: No player has more than 5% market share - Used to illustrate how fragmented the life sciences industry remains Mega-merger activity since last major wave: Few really large or “mega” mergers since 2009 - Supports the view that consolidation could still intensify Tax uncertainty timing: 2017 uncertainty around tax legislation - Seen as a factor that may have held back M&A activity Firepower factors: Cash available, debt capacity, and market capitalization - The components of EY’s Firepower Index Technology-company comparison: Tech companies’ firepower is at least on par with, if not in excess of, the entire group of ~65 life sciences companies - Illustrates nontraditional buyers’ potential buying power Conference date mentioned in sponsor readout: October 15th and 16th, 2025 - Referenced in the opening sponsor message for Prevail Infoworks Podcast subscription reference: Weekly RSS feed or iTunes - Mentioned in the closing housekeeping segment

Pivotal Quotes: "Firepower is really a basic measure of the financial capacity to invest in M&A." — Jeff Green: Explaining EY’s Firepower Index "This industry is ... still relatively fragmented." — Jeff Green: On why consolidation and mega-mergers remain plausible "I think it’s inevitable that we see one, if not more, substantial investments." — Jeff Green: Discussing the likelihood of nontraditional players making a big splash

Implications: Expect a more competitive M&A market where capital-rich buyers, including tech and Asian firms, bid for premium assets. Sellers gain leverage, while buyers must justify deals strategically and financially or risk overpaying.